Expert opinion on pharmacotherapy of narcolepsy

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 10, 2010, Pages 1633-1645

  Zaharna, Mia ^a   Dimitriu, Alex ^a   Guilleminault, Christian ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cataplexy; Hypocretin; Medication; Narcolepsy; Orexin; Pharmacology; Pharmacotherapy; Sleep; Treatment

Indexed keywords

4 HYDROXYBUTYRIC ACID; ANTIDEPRESSANT AGENT; ARMODAFINIL; ATOMOXETINE; CAFFEINE; CLOMIPRAMINE; DESIPRAMINE; DEXAMPHETAMINE; DULOXETINE; FLUNITRAZEPAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; MONTIRELIN; OREXIN A; OROTIRELIN; OXYBATE SODIUM; PEMOLINE; PROTIRELIN; PROTRIPTYLINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TALTIRELIN; TEMAZEPAM; THIOPERAMIDE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ABDOMINAL PAIN; ATTENTION DEFICIT DISORDER; AUTOIMMUNITY; AUTOMATISM; CATAPLEXY; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DAYTIME SOMNOLENCE; DECREASED APPETITE; DEPRESSION; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; IMMUNOTHERAPY; LIBIDO DISORDER; LIVER TOXICITY; LOW DRUG DOSE; MAJOR DEPRESSION; MICTURITION DISORDER; NARCOLEPSY; NAUSEA; NONHUMAN; PERIPHERAL NEUROPATHY; REBOUND; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP FRAGMENTATION; SLOW WAVE SLEEP; SOMNOLENCE; STATUS CATAPLECTICUS; SUBSTITUTION THERAPY; TACHYCARDIA; VOMITING; WAKEFULNESS; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZHYDRYL COMPOUNDS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; HYPNOTICS AND SEDATIVES; IMMUNOTHERAPY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES; SEROTONIN UPTAKE INHIBITORS; SODIUM OXYBATE;

EID: 77953625659     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.484021     Document Type: Review

References (105)

1. American Academy of Sleep Medicine; European Sleep Research Society. International Classification of Sleep Disorders, 2nd edition. Diagnostic and coding manual. American Academy of Sleep Medicine Westchester, IL; 2005
2. Hublin C, Kaprio J, Partinen M, et al. The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann Neurol 1994;11:709-716
3. Ohayon MM, Priest RG, Zulley J, et al. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002;58:1826-1833
4. Silber MH, Krahn LE, Olson EJ, et al. The epidemiology of narcolepsy in Olmsted county, Minnesota: a population-based study. Sleep 2002;25:197-202
5. Wing YK, Li RH, Lam CW, et al. The prevalence of narcolepsy among Chinese in Hong-Kong. Ann Neurol 2002;51:578-584
6. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005;9:269-310
7. Overeem S, Mignot E, Van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001;18:78-105
8. Nishino S, Okura M, Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 2000;4:57-99
9. Chabas D, Taheri S, Renier C, Mignot E. The genetics of narcolepsy. Annu Rev Genomics Hum Genet 2003;4:459-483
10. Ripley B, Fujiki N, Okura M, et al. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001;8:525-534 (Pubitemid 32566142)
11. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin(orexin) receptor 2 gene. Cell 1999;98:365-376
12. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-997
13. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-474
14. Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2000;50:381-388
15. Mignot E, Lin X, Arrigoni J, et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and Black Americans. Sleep 1994;17(Suppl 8):60-67
16. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50(2 Suppl 1):16-22
17. Mignot E, Hayduk R, Black J, et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997;20:1012-1020 (Pubitemid 28042450)
18. Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007;8:373-399
19. Littner M, Johnson SF, McCall WV, et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001;24:451-466
20. Physician's Desk . Montvale, NJ: Medical Economics, 2005
21. US Food and Drug Administration (FDA). InfoSheets; 2005. Available from: http://www.fda. gov/cder/drug/InforSheets/HCP/ pemolineHCP.pdf [Last accessed 2 Feb 2010]
22. Mitler MM, Aldrich MS, Koob GF, Zarconne VP. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994;17:352-371
23. Kuczenski R, Segal DS. Effects of methyphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997;68:2032-7. Erratum in J Neurochem 1997;69:1332
24. Mignot E, Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 2005;28:754-763
25. Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatr Dis Treat 2008;4:557-566
26. Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-1794
27. Qu WM, Huang ZL, Xu XH, et al. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci 2008;28:8462-8469
28. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8628
29. Ferraro L, Tanganelli S, O'Conoor W, et al. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996;306:33-39
30. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
31. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-1175
32. Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med 2000;1:109-116
33. Billiard M, Nicolet A, Dauvilliers Y, et al. Modafinil: the European experience. In: Bassetti C, Billiard M, Mignot E, editors, Narcolepsy and hyperosmnia. Informa Healthcare, New York; 2007. p. 561-569
34. Thorpy MJ, Black J, Erman MK. The safety profile of modafinil in disorders of sleep and wakefulness. Neurology 2004;62(Suppl 5):A56-7
35. Broughton RJ, Fleming JAE, George CFP, et al. Randomized, double-blind placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-451
36. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
37. Beuersterien KM, Rogers AAE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999;22:757-765
38. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-1175
39. Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicenter study. Sleep 1994;17(Suppl):107-112
40. Erman MK, Hirshowitz M, Schwartz JR. Modafinil improves wakefulness and clinical condition in obstructive sleep apnea. Presented at the 70th Annual Meeting of the American College of Chest Physicians; 27 October 2004; Seattle, WA, USA
41. Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 2003;4:579-582
42. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22:761-774
43. Bonaventure P, Letavic M, Dugovic C. Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 2007;73:1084-1096
44. Jenner P, Zeng B-Y, Smith LA, et al. Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset. Exp Brain Res 2000;133:178-188
45. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30:205-211
46. Makris AP, Rush CR, Frederich RC, Kelly TH. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 2004;42:185-195
47. Kushida CA. Countermeasures for sleep loss and sleep deprivation. Curr Treat Options Neurol 2006;8:361-366
48. De Valck E, De Groot E, Cluydts R. Effects of slow-release caffeine and a nap on driving simulator performance after partial sleep deprivation. Percept Mot Skills 2003;96:67-78
49. Walsh JK, Muehlbach MJ, Schweitzer PK. Hypnotics and caffeine as countermeasures for shiftwork-related sleepiness and sleep disturbance. J Sleep Res 1995;4:80-83
50. Martinez-Rodriguez J, Iranzo A, Santamaria J, et al. Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia 2002;17:113-116
51. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 1960;21:704-706
52. Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatr Dis Treat 2008:4:557-566
53. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52:27-78
54. Plazzi G, Montagna P, Provini F, et al. Treatment of narcolepsy with cataplexy. Lancet 2007;369:1081
55. Izzi F, Placidi F, Marciani MG, et al. Effective treatment of narcolepsy-cataplexy with duloxetine: a report of three cases. Sleep Med 2009;10:153-154
56. Niederhofer H. Atomoxetine also effective in patients suffering from narcolepsy? Sleep 2005;28:1189
57. Terzano MG, Mancia D, Salati MR, et al. The cyclic alternating pattern as a physiological component of normal NREM sleep. Sleep 1985;8:137-145
58. Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs. Rev Psychopharmacol (Berl) 1996;126:1-16
59. Terzano M, Smerieri A, Del Felice A, et al. Cyclic alternating pattern (CAP) alterations in narcolepsy. Sleep Med 2006;7:619-626 (Pubitemid 44804235)
60. Maitre M, Humbert JP, Kemmel V, et al. A mechanism for gamma-hydroxybutyrate (GHB) as a drug and a substance of abuse [in French]. Med Sci (Paris) 2005;21:284-289
61. US Xyrem Multicenter Study Group. A randomized, double blind placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-49
62. US Xyrem Multicenter Study Group. A 12-month open-label multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26:31-35
63. US Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-123
64. Black J, Ristanovic R, Mamelak M, Montplaisir J. Dose response effects of sodium oxybate on polysomnographic (PSG) measures in narcolepsy patients; preliminary findings. Sleep 2001;24(Suppl):A321
65. Hayduk R, Mitler MM. Sodium oxybate therapy improves the quality of life of narcolepsy patients. Sleep 2001;24(Suppl):A326
66. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006;2:939-946
67. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind placebocontrolled study in 228 patients. Sleep Med 2005;6:415-421
68. Jazz pharmaceuticals. Xyrem (sodium oxybate) oral solution. Available at: http://jazzph.isat-tech.com/media/PI.pdf [Last accessed 2 February 2010]
69. Soares CN, Murray BJ. Sleep disorders in women: clinical evidence and treatment strategies. Psychiatr Clin North Am 2006;29:1095-1113
70. Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy. Neurology 2004;63:1065-1069
71. Edwards N, Middleton PG, Blyton DM, Sullivan CE. Sleep disordered breathing and pregnancy. Thorax 2002;57:555-558
72. Kent JM. SnaRIs, NaSSAs, and NARIs: new agents for the treatment of depression. Lancet 2000;355:911-18, Erratum in: Lancet 2000;355:2000
73. Beer B, Stark J, Krieter P, et al. DOV 216,303, a 'triple' reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol 2004;44:1360-1367
74. Nishino S, Arrigoni J, Shelton J, et al. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997;17:6401-6408
75. Riehl J, Honda K, Kwan M, et al. Chronic oral administration of CG-3703, a thyrotropin-releasing hormone analog, increase wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology 2000;23:34-45
76. Nicoll RA. Excitatory action of TRH on spinal motoneurons. Nature 1977;265:242-243
77. González JA, Horjales-Araujo E, Fugger L, et al. Stimulation of orexin/ hypocretin neurons by thyrotropin-releasing hormone. J Physiol 2009;587:1179-1186
78. Griffiths EC, Bennett GW. Clinical applications of thyrotropin-releasing hormone. Clin Sci 1987;73:449-457
79. Vogel HP, Benkert O, Illig R, et al. Psychoendocrinological and therapeutic effects of TRH in depression. Acta Psychiatr Scand 1977;56:223-232
80. Bunevicius R, Matulevicus V. Short-lasting behavioural effects of thyrotropin-releasing hormone in depressed women: results of placebo-controlled study. Psychoneuroendocrinology 1993;18:445-449
81. Lin JS. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 2000;4:471-503
82. Shiba T, Fujiki N, Wisor JP, et al. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ ataxin-3 narcoleptic mice. Sleep 2000;27(Suppl):SA241-2
83. Tedford CE, Edgar DM, Seidel WF, et al. Effects of a novel, selective and potent histamine H3 receptor antagonist, GT-2332, on rat sleep/wakefulness and canine cataplexy. Abstr Soc Neurosci 1999;25:1134
84. Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008;30:74-83
85. Silber MH, Black JL, Krahn LE, et al. Autoimmune studies in narcolepsy. In: Bassetti C, Billiard M, Mignot E, editors, Narcolepsy and Hypersomnia. Informa Healthcare, New York; 2007. p. 451-457
86. Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009;32:979-983
87. Lecendreux M, Maret S, Bassetti C, et al. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003;12:347-348
88. Hect M, Ling L, Kushida C, et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin- deficiency narcolepsy. Sleep 2003;26:809-810
89. Dauvilliers Y, Carlander B, River F, et al. IVIG treatment in narcolepsy: report on two new cases. J Sleep Res 2004;13(Suppl 1):167
90. Zuberi SM, Mignot E, Ling L, MacArthur I. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. J Sleep Res 2004;13(Suppl 1):828
91. Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 2005;58:489-490
92. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-997
93. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-474
94. Kastin AJ, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 1999;289:219-223
95. Yoshida Y, Fujiki N, Maki RA, et al. Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats. Neurosci Lett 2003;346:182-186
96. Fujiki N, Ripley B, Yoshida Y, et al. Effects of IV and ICV hpocretin-1 (orexin-A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep 2003;6:953-959
97. John J, Wu MF, Siegel JM. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 2000;3:23-28
98. Hanson LR, Martinez PM, Taheri S, et al. Intranasal administration of hypocretin 1 (Orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Deliv Technol 2004;4:66-71
99. Hallschmid M, Benedict C, Born J, et al. Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man. Physiol Behav 2004;83:55-64
100. Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27:14239-14247
101. Croston GE, Olsson R, Currier EA, et al. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954). J Med Chem 2002;45:4950-4953
102. Zaveri N. Peptide and nonpeptide ligands for the nociceptine/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci 2003;73:663-678
103. Saar K, Mazarati AM, Mahlapuu R, et al. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci USA 2002;99:7136-7141
104. Arias-Carrion O, Murillo-Rodriguez E, Xu M, et al. Transplant of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 2004:27:1465-1470
105. Huang YS, Guilleminault C. Narcolepsy: action of two gamma aminobutyric acid type B agonists, Baclofen and sodium oxybate. Pediatr Neurol 2009;41:9-16